The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-05), Cardiff Oncology's 9-Day RSI is 41.24.
The industry rank for Cardiff Oncology's 9-Day RSI or its related term are showing as below:
CRDF's 9-Day RSI is ranked better than 78.91% of 1418
companies
in the Biotechnology industry
Industry Median: 53.73
vs CRDF: 41.24
Cardiff Oncology (NAS:CRDF) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Cardiff Oncology 9-Day RSI Related Terms
CRDF vs MAIA, TELO, OSTX: 9-Day RSI Comparison
For the Biotechnology subindustry, Cardiff Oncology's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (CRDF) has a 9-Day RSI of 41.24 as of Jul. 05, 2026. According to the industry distribution chart, Cardiff Oncology ranks #299 out of 1418 companies in the Biotechnology industry, placing it in the top 21.1%.
Is Cardiff Oncology's 9-Day RSI too high?
Cardiff Oncology's current 9-Day RSI is 41.24. The Biotechnology industry median 9-Day RSI is 53.73. Cardiff Oncology's value of 41.24 is 23.2% below this industry median. Based on the distribution chart, Cardiff Oncology ranks #299 out of 1418 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cardiff Oncology has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's 9-Day RSI compare to MAIA and TELO?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #299 out of 1418 companies for 9-Day RSI. This places Cardiff Oncology in the top 21% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 53.73. Cardiff Oncology's value of 41.24 is 23.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 53.73, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current 9-Day RSI of 41.24 is 23.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 53.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current 9-Day RSI is 41.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.44, compared to a current price of $1.27 — trading 11.8% below its estimated fair value. The current 9-Day RSI is 41.24 and 23.2% below the Biotechnology industry median of 53.73. Cardiff Oncology's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current 9-Day RSI is 41.24 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Oncology (CRDF) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued.
The current stock price of $1.27 is trading 11.8% below its estimated GF Value™ of $1.44.
GuruFocus considers Cardiff Oncology to be Modestly Undervalued.
Key valuation signals for CRDF:
9-Day RSI: 41.24
GF Value™: $1.44 vs. price of $1.27 (11.8% below fair value)
Industry Position: 23.2% below the Biotechnology median (#299 of 1418)
No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
49GF Score
Get the complete analysis for CRDF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 